Clinical research has primarily employed intravenous infusions at high doses, though subcutaneous administration at lower doses is emerging as a practical maintenance route [2] [3]
[PMC free article: PMC3195668] [PubMed: 22022289] 126
10.1007/s11105-012-0524-5 Plant Mol
The route of administration significantly impacts treatment speed
doi: 10.1111/j.1582-4934.2004.tb00275.x
Composition GHK-Cu: 50 mg KPV: 10 mg BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of copper peptide, KPV tripeptide, BPC-157, and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of four co-formulated peptides Stability characterization of a four-analyte lyophilized blend under laboratory storage conditions Method documentation for HPLC/LC-MS identity and purity assessments Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
-1775582746855.png&w=3840&q=75)
